# C_2004111EN.01000201.xml

| 30.4.2004 | EN | Official Journal of the European Union | C 111/2 |
| --- | --- | --- | --- |

30.4.2004

EN

Official Journal of the European Union

C 111/2

---

Prior notification of a concentration

(Case No. COMP/M.3449-GlaxoSmithKline/Sanofi-Synthélabo (assets))

Candidate case for simplified procedure

(2004/C 111/02)

(Text with EEA relevance)

| 1. | On 19 April 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (1), as last amended by Regulation (EC) No 1310/97 (2), by which the undertaking GlaxoSmithKline plc (‘GSK’, UK) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of parts of the undertaking Sanofi-Synthélabo SA (‘Sanofi’, France) by way of purchase of assets. |
| --- | --- |

1.

On 19 April 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (1), as last amended by Regulation (EC) No 1310/97 (2), by which the undertaking GlaxoSmithKline plc (‘GSK’, UK) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of parts of the undertaking Sanofi-Synthélabo SA (‘Sanofi’, France) by way of purchase of assets.

1

2

| 2. | The business activities of the undertakings concerned are:






  — | GSK: Pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

GSK: Pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products;

| — | Sanofi: Human pharmaceuticals. |
| --- | --- |

—

Sanofi: Human pharmaceuticals.

| 3. | On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EEC) No 4064/89. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No4064/89 (3) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EEC) No 4064/89. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No4064/89 (3) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

3

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax no. (32-2) 296 43 01 or 296 72 44) or by post, under reference COMP/M.3449-GlaxoSmithKline/Sanofi-Synthélabo (assets), to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax no. (32-2) 296 43 01 or 296 72 44) or by post, under reference COMP/M.3449-GlaxoSmithKline/Sanofi-Synthélabo (assets), to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 395, 30.12.1989 p. 1; corrigendum: OJ L 257, 21.9.1990, p. 13.

1

(2)  OJ L 180, 9.7.1997, p. 1; corrigendum OJ L 40, 13.2.1998, p. 17.

2

(3)  OJ C 217, 29.7.2000, p. 32.

3

---